

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-10. (cancelled)


11. (currently amended) A method for the treatment and/or prevention of metabolic syndrome, whereby a pharmaceutically and pharmacologically effective amount of an angiotensin II type 1 receptor antagonist alone or in combination with a ~~calcium antagonist~~ metabolically neutral antihypertensive substance is administered to a subject in need of such treatment or prevention.

12. (currently amended) A ~~The method according to~~ The method according to claim 11, wherein the angiotensin II type 1 receptor antagonist is of the general formula I:




I


wherein A is ~~selected from the group consisting of~~




I:1




I:2




I:3




I:4




I:5




I:6




I:7




I:8




I:9




I:10



I:11



I:12

or and

I:13

or pharmaceutically acceptable salts, solvates or stereochemical isomers thereof ~~of any of these~~,
or solvates of such salts.

13. (currently amended) A The method ~~according to~~ of claim 12, wherein A is I:5.
14. (currently amended) A The method ~~according to~~ of claim 12, wherein A is I:13.
15. (currently amended) A The method ~~according to~~ of any one of claims 11-14, wherein the metabolically neutral antihypertensive substance is a calcium antagonist.
16. (currently amended) A The method ~~according to~~ of claim 15, wherein the metabolically neutral antihypertensive substance is selected from amlodipine, verapamil, nifedipine,

nimodipine, diltiazem, nicardipine, felodipine, emlodipine, ryosidine, lacidipine, niguldipine, niludipine, nisoldipine, nitrendipine, nivaldipine, isradipine, flunarizine, diltiazem, mibefradil, prenylamine, fendiline, gallopamil, verapamil, tiapamil and anipamil, ~~as well as, in each case, or~~ a pharmaceutically acceptable salt thereof.

17. (currently amended) The method ~~according to~~ of any one of claims 11-~~14~~ 16, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.01 mg to about 1000 mg.

18. (currently amended) The method ~~according to~~ of claim 17, wherein ~~wherein~~ the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to 750 mg.

19. (currently amended) The method ~~according to~~ of claim 18, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 1 mg to 500 mg.

20. (currently amended) The method ~~according to~~ of claim 13, wherein the daily dose of the angiotensin II type 1 receptor antagonist is from about 0.1 mg to about 300 mg per day calculated as candesartan.